Jazz Pharmaceuticals (JAZZ) Q1 2026 Earnings
Reported May 5, 2026 at 4:06 PM ET · SEC Source
Q1 26 EPS
$6.34
BEAT +36.18%
Est. $4.66
Q1 26 Revenue
$1.07B
BEAT +9.18%
Est. $979.0M
vs S&P Since Q1 26
+5.1%
BEATING MARKET
JAZZ +6.1% vs S&P +1.0%
Market Reaction
Did JAZZ Beat Earnings? Q1 2026 Results
Jazz Pharmaceuticals delivered a standout first quarter for fiscal 2026, posting non-GAAP adjusted EPS of $6.34 against a consensus estimate of $4.66, a beat of 36.18%, while revenue climbed 19.1% year-over-year to $1.07 billion, exceeding analyst ex… Read more Jazz Pharmaceuticals delivered a standout first quarter for fiscal 2026, posting non-GAAP adjusted EPS of $6.34 against a consensus estimate of $4.66, a beat of 36.18%, while revenue climbed 19.1% year-over-year to $1.07 billion, exceeding analyst expectations of $979.01 million by 9.18%. The headline driver behind the earnings strength was broad commercial momentum across the company's core franchises, with Xywav contributing $408.20 million as the largest single revenue source, Epidiolex growing 15% to $249.80 million, and Zepzelca surging 60% to $101.00 million on the strength of its atezolizumab combination in small cell lung cancer. A $122.80 million gain from the sale of a Rare Pediatric Disease Priority Review Voucher further supported GAAP results, helping swing net income to $293.10 million from a loss of $92.50 million a year ago. Shares reached notable highs in the wake of the report, reflecting investor confidence in Jazz's diversified portfolio. Management reaffirmed full-year 2026 revenue guidance of $4.25 billion to $4.50 billion, with a potential zanidatamab approval in gastroesophageal adenocarcinoma carrying a PDUFA date of August 25, 2026.
Key Takeaways
- • Strong Xywav demand with 425 net patient adds reaching ~16,600 active patients
- • Zepzelca revenues grew 60% YoY driven by uptake of Zepzelca and atezolizumab combination in 1LM ES-SCLC
- • Epidiolex continued consistent demand-driven growth of 15% YoY
- • Modeyso contributed $41 million in its first full quarter following August 2025 launch
- • SG&A declined significantly due to $172 million Xyrem antitrust litigation settlements in 1Q25 not recurring
- • $122.8 million gain on sale of Priority Review Voucher
JAZZ Forward Guidance & Outlook
Jazz Pharmaceuticals reaffirmed its full-year 2026 revenue guidance of $4,250 million to $4,500 million. The company also reaffirmed expense guidance: GAAP gross margin of 89%-90%, GAAP SG&A of $1,424-$1,497 million, GAAP R&D of $811-$867 million, and GAAP effective tax rate of 0%-10%. Non-GAAP gross margin is guided at 90%-91%, non-GAAP SG&A of $1,260-$1,320 million, non-GAAP R&D of $725-$775 million, and non-GAAP effective tax rate of 11.5%-13.5%. Weighted-average shares outstanding guidance was updated to 66-67 million. The company expects second-line Zepzelca use to decline throughout the year. The zanidatamab sBLA in 1L HER2+ GEA has a PDUFA date of August 25, 2026, with potential approval and launch on or before that date. The Phase 3 ACTION trial for Modeyso has a top-line readout expected late 2026/early 2027.
JAZZ YoY Financials
Q1 2026 vs Q1 2025, source: SEC Filings
JAZZ Revenue by Segment
With YoY comparisons, source: SEC Filings
“Our first-quarter results reflect disciplined execution across the business, delivering 19% year-over-year growth alongside key pipeline advancements and positioning the company for an outstanding 2026.”
— Renee Gala, Q1 2026 Earnings Press Release
JAZZ Earnings Trends
JAZZ vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
JAZZ EPS Trend
Earnings per share: estimate vs actual
JAZZ Revenue Trend
Quarterly revenue: estimate vs actual
JAZZ Quarterly Results
4 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 BEAT | $4.66 | $6.34 | +36.18% | $1.07B | +9.18% |
| Q4 25 BEAT FY | $6.51 | $6.64 | +2.05% | $1.20B | +2.81% |
| FY Full Year | — | $8.38 | — | $4.27B | — |
| Q3 25 BEAT | $5.85 | $8.13 | +38.97% | $1.13B | +1.58% |
| Q2 25 MISS | $-6.25 | $-8.25 | -32.07% | $1.05B | -0.14% |